Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA, CMS To Standardize Regulatory Analytical Tools

Executive Summary

FDA, CMS and other agencies within the Department of Health and Human Services will combine forces to improve and standardize analytical tools used in regulatory decision-making.

You may also be interested in...

IPAB Will Make CMS More Relevant In Parallel Reviews With FDA, Former Official Gottlieb Predicts

BALTIMORE – Decisions by the soon-to-be-created Independent Payment Advisory Board could make CMS participation in parallel review of drugs with FDA much more meaningful than it would otherwise be, assuming the health care reform law remains intact, former CMS and FDA official Scott Gottlieb said.

PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue

FDA and industry have reached agreement on four issues in the Prescription Drug User Fee Act reauthorization, including adjustments to risk-benefit policy and creation of a meta-analysis team.

Transparency Phase III: FDA Offers Designs For Industry Review

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts